OE33
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
The OE33 cell line, also known as JROECL33, was established from a 73-year-old female patient with adenocarcinoma originating in the lower esophagus, specifically associated with Barrett’s metaplasia. The tumor was diagnosed as pathological stage IIA (UICC) and exhibited poor differentiation. OE33 cells continuously express HLA-A, -B, and -C antigens (MHC class I), along with ICAM-1. The introduction of interferon-gamma can induce the expression of HLA-DR (MHC class II) in these cells. They display epithelial cytokeratins such as CK7, CK8, CK18, and CK19, while CK17 is notably absent. Moreover, OE33 cells express EpCAM but lack desmin, endothel, GFAP, neurofilament, and vimentin. Notably, they possess tumorigenic potential when transplanted into nude mice.
Why choose OE33 from AcceGen?
The OE33 cell line from AcceGen offers exceptional features, characterized by its high viability and quality, cultivated under ideal conditions. It maintains sterility and consistently tests negative for bacteria, yeast, mycoplasma, and a spectrum of pathogens including HIV, HBV, HCV, HPV, HTLV, and MLV. Identity verification is assured through STR analysis, and stringent quality control measures further guarantee its reliability.
| Product Code | OE-33; JROECL 33; JROECL33; OEC33 |
| Species | Human |
| Cat.No | ABC-TC510S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Esophagus |
| Disease | Esophageal Cancer |
| Storage | Liquid Nitrogen |
| Product Type | Human Esophageal Cancer Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The OE33 cell line serves as a valuable, continuous resource for both research and therapeutic advancement in the realm of esophageal adenocarcinoma. It plays a pivotal role in the investigation of the disease, aiding in a deeper understanding of its pathogenesis and progression. Moreover, OE33 cells are instrumental in the development of innovative treatment strategies for esophageal adenocarcinoma, serving as an indispensable tool for preclinical drug testing and the exploration of potential therapeutic interventions, ultimately contributing to improved patient outcomes in the battle against this challenging malignancy.
